Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
oxfordimmunotec.com

See what CB Insights has to offer

Founded Year

2002

Stage

Acq - P2P | Acquired

Total Raised

$106.35M

Valuation

$0000 

Revenue

$0000 

About Oxford Immunotec

Oxford Immunotec (NASDAQ:OXFD) is a global diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions. T-SPOT is their platform technology, designed to simply and accurately examine a patient's cellular immune response to infection; the first product to come from this platform is the T-SPOT.TB Test, which is used to test for tuberculosis infection. The company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisition of Imugen. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company's third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions.On January 7th, 2021, Oxford Immunotec was acquired by PerkinElmer at a valuation of $591M.

Oxford Immunotec Headquarter Location

115D Innovation Drive Milton Park, Abingdon

Oxfordshire, England, OX14 4RZ,

United Kingdom

+44 (0) 1235 442 780

Latest Oxford Immunotec News

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection.

May 19, 2021

. OXFORD, United Kingdom and MARLBOROUGH, Mass., 18th May, 2021 (GLOBE NEWSWIRE) – Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer , today announced that its T-SPOT® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector. The study is funded by the Department of Business, Energy, and Industrial Strategy (BEIS) through the UK Vaccines Taskforce and is being delivered through a partnership between government, hVIVO (part of Open Orphan plc ), Imperial College London, and The Royal Free London NHS Foundation Trust. The groundbreaking UK COVID-19 Human Challenge Study has global importance as the first study of its type in the world, and the data generated should help to develop vaccines against COVID-19 much more quickly and efficiently. The first stage of the trial, which commenced in March, will enable identification of the most appropriate dose of the virus needed to cause COVID-19 (SARS-CoV-2) infection in a safe and controlled environment. The participants will have a complete analysis of their immune response to infection carried out (including T cells) which should lead to a better understanding of the profile, magnitude, and duration of the immune response to SARS-CoV-2. This study will therefore establish an optimised dose and study design that will subsequently be used to evaluate the efficacy of treatment and vaccine candidates, including level and duration of immune protection, in follow-on studies. A custom version of Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 kit (for research use only) will be used in this study. The kit uses the T-SPOT technology platform, a standardized ELISPOT methodology, to detect the T cell immune response in study subjects. Understanding the T cell immune response, in addition to the antibody response (via serology), may offer additional insights into how the complete immune system responds to infection and vaccination. As T cells are the first responders of the immune system and are known to be long lived , using T cells to measure immune response may overcome some of the limitations of serology testing . A CE marked IVD version of the kit (the T-SPOT.COVID test) is also available from Oxford Immunotec. Dr. Magdalena Dudek, VP, Product Development at Oxford Immunotec said, “The UK COVID-19 Human Challenge Study has global significance, and the potential to be a much more efficient and faster way to understand the disease and how our immune system fights it. We are very excited to be a part of this trial which should accelerate the development of vaccines and treatments against COVID-19. We are proud of our continual partnership with the UK Vaccines Taskforce which enables us to provide T cell testing for this critical clinical trial.” For further information about the study visit: www.ukcovidchallenge.com   For further information visit: www.tspotdiscovery.com T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures. About Oxford Immunotec Oxford Immunotec is a global, high-growth diagnostics company and part of the PerkinElmer group. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. Oxford Immunotec is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States (where it has received pre-market approval from the Food and Drug Administration), Europe (where it has obtained a CE mark), as well as Japan and China. The recently released T-SPOT.COVID test is CE marked in Europe for clinical use to detect the T cell immune response to SARS-CoV-2 ( www.tspotcovid.com ). Oxford Immunotec is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com . About PerkinElmer PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com . For Media Inquiries:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxford Immunotec

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Immunotec is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,579 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Oxford Immunotec Patents

Oxford Immunotec has filed 6 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Cytokines
  • Honeycombs (geometry)
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/27/2017

9/7/2021

Immunology, Immune system, Clusters of differentiation, Vaccines, Cytokines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/27/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Clusters of differentiation, Vaccines, Cytokines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Oxford Immunotec Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Immunotec Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.